2.41
Precedente Chiudi:
$2.46
Aprire:
$2.48
Volume 24 ore:
98,838
Relative Volume:
0.54
Capitalizzazione di mercato:
$7.29M
Reddito:
-
Utile/perdita netta:
$-31.88M
Rapporto P/E:
-3.2133
EPS:
-0.75
Flusso di cassa netto:
$-25.20M
1 W Prestazione:
+9.55%
1M Prestazione:
+7.59%
6M Prestazione:
-70.79%
1 anno Prestazione:
-90.50%
In 8 Bio Inc Stock (INAB) Company Profile
Nome
In 8 Bio Inc
Settore
Industria
Telefono
(646) 600-6438
Indirizzo
EMPIRE STATE BUILDING, NEW YORK
Confronta INAB con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
INAB
In 8 Bio Inc
|
2.41 | 8.47M | 0 | -31.88M | -25.20M | -0.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-03-18 | Iniziato | Laidlaw | Buy |
2022-08-30 | Iniziato | H.C. Wainwright | Buy |
In 8 Bio Inc Borsa (INAB) Ultime notizie
Will Passage Bio Inc. stock benefit from interest rate changesAccelerated earnings growth - jammulinksnews.com
Layoff Tracker: Flagship Unicorns Tessera, Generate:Biomedicines Downsize - BioSpace
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference - Stock Titan
Tourmaline Bio Inc. Stock Analysis and ForecastHigh-yield market plays - jammulinksnews.com
Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire
What analysts say about 2seventy bio Inc. stockExceptional return forecasts - Autocar Professional
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - The Globe and Mail
What drives Mustang Bio Inc. stock priceMarket-leading growth rates - jammulinksnews.com
What analysts say about TELA Bio Inc. stockBreakout stock performance - Jammu Links News
Upstream Bio, Inc. shares fall 4.98% premarket after HBM Healthcare Investments reports an 8.4% decline in NAV per share. - AInvest
What drives Boundless Bio Inc. stock pricePowerful profit generation - jammulinksnews.com
Gossamer Bio Inc. Stock Analysis and ForecastMarket-leading capital gains - jammulinksnews.com
Why Climb Bio Inc. stock attracts strong analyst attentionEntry Level Low Risk Picks - Newser
Why Kronos Bio Inc. stock attracts strong analyst attentionFree Stock Investment Discussion Area - Newser
Why Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors - GlobeNewswire
Pre-market Movers: CLDI, BMGL, PROK, RXST... - RTTNews
KALA BIO Announces Completion of Enrollment in CHASE - GlobeNewswire
Cizzle Bio Submits NIH Grant Proposal with Premier Research Institutions to Advance Biomarker Blood Test for Lung Cancer - Yahoo Finance
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma - Yahoo Finance
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to - GlobeNewswire
Clinical-Stage Biotech INmune Bio Secures $19M Through Strategic Share Offering - Stock Titan
Breakthrough: New Alzheimer's Drug XPro Shows Promise in Key Patient Group, Zero ARIA Cases - Stock Titan
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Clinical-Stage Immunology Company INmune Bio Secures $19M from Healthcare Investors at Market Price - Stock Titan
Major Alzheimer's Treatment Milestone: INmune Bio Reveals Phase 2 Trial Results Next Week - Stock Titan
BioCryst's ORLADEYO Pediatric HAE Review Extended by FDA to December 2025 | BCRX SEC FilingForm 8-K - Stock Titan
Breakthrough in Dementia Treatment: Gene Therapy Maintains 18-Month Efficacy with Lower Dose Success - Stock Titan
ANVS gains NYSE approval of compliance plan, delisting risk eased | ANVS SEC FilingForm 8-K - Stock Titan
Global Protein Expression Market to Observe Growth at a CAGR of ~8% by 2032 | DelveInsight - GlobeNewswire
Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements (NYSE:NUVB) - Seeking Alpha
U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer - Quantisnow
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress - Yahoo Finance
Breakthrough: New Drug Reduces Alzheimer's Risk After Brain Injury, DoD-Backed Study Shows - Stock Titan
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial - GlobeNewswire Inc.
European Launch: TELA Bio's Natural Hernia Repair Device Shows 98.8% Success Rate - Stock Titan
TELA Bio Appoints Jeffrey Blizard as President - GlobeNewswire
Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews
KALA BIO to Present at Jefferies Global Healthcare Conference - GlobeNewswire
Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) Price Target at $20.33 - MarketBeat
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis - GlobeNewswire
Global Immunoprecipitation Market Set to Grow at a CAGR of 6-8%: Key Drivers and Challenges by 2029 - PharmiWeb.com
DNA Polymerase Market to Grow at 6–8% CAGR Driven by Genomics, PCR, and CRISPR Technologies by 2029 - PharmiWeb.com
GRI Bio Presents Positive Pre-Clinical Data Demonstrating - GlobeNewswire
Caisse Française de Financement Local: EMTN 2025-8 SOCIAL - The Manila Times
Protagenic Therapeutics Completes Acquisition of Phytanix Bio - TipRanks
Dimensional Fund Advisors LP Sells 592,968 Shares of bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
GRI Bio CEO Reveals Latest Developments in Revolutionary NKT Cell Technology at Major Healthcare Conference - Stock Titan
KALA BIO: Q1 Earnings Snapshot - The Washington Post
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Raymond James Financial Inc. Takes Position in 8×8, Inc. (NASDAQ:EGHT) - Defense World
In 8 Bio Inc Azioni (INAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):